search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
The latest Business updates from the science industry


by Heather Hobbs Sovereign Investment Partnership to boost UK Life Sciences Sector


Over a fi ve-year period, the SIP will invest across several tech and innovation-led sectors such as energy transition and infrastructure that will support job creation in both nations, strengthen national research and development capabilities and develop new areas of investment collaboration.


UK International Trade Secretary Liz Truss said: “The UAE is an important trading partner for the UK and home to some of the world’s largest and most experienced investment companies. It’s fantastic that we are collaborating more closely in the industries of tomorrow like science, tech and green growth, so we can build back better and deliver an investment- led, jobs-led recovery from coronavirus.


A long-term UAE-UK Sovereign Investment Partnership (SIP) agreement that will initially see investment of £1 billion in British life science companies has been announced by The Department for International Trade and the Prime Minister’s Offi ce’s recently-established UK Offi ce for Investment (OfI) and Abu Dhabi’s Mubadala Investment Company, one of the world’s leading sovereign investors.


The signing, the fi rst agreement of its kind for the UK and the OfI, will deepen existing UK-UAE trade and investment ties which were worth £32 billion in 2019.


The £800 million commitment from Mubadala, alongside the UK’s £200 million Life Sciences Investment Programme announced last year, will enable UK life sciences businesses to scale and grow, with both OfI and Mubadala working together to identify commercially viable opportunities for attracting further investment into the sector.


The UK life sciences industry which generates £80 billion turnover a year within the UK and employs more than 250,000 people, is expected to benefi t from stronger links in life sciences research, education and closer ties between the UAE and UK.


“This is a major win for the Offi ce for Investment and shows how the UK is an investment destination of choice. From Liverpool and Edinburgh to Oxford and Nottingham, our world class life sciences clusters and innovative businesses will see the benefi ts of this partnership.”


Khaldoon Khalifa Al Mubarak, Managing Director and Group CEO of Mubadala commented: The UAE and UK are aligned on the importance of global action on critical


priorities such as healthcare


innovation and delivery, climate change and the sustainable growth of high-skilled industries.


“Coordination on investment and global innovation ecosystems is vital to enabling progress against these challenges and presents a signifi cant post-COVID economic opportunity for the UK and UAE.


Mubadala is already a long-term investor in UK innovation and growth, and our new partnership now provides a platform to allocate stable capital to priority sectors as part of a future-focused investment relationship.”


More information online: ilmt.co/PL/EJ1R 54947pr@reply-direct.com


Acquisition maintains Focus on Medical Devices The Ulkox® and Oleoabrax® products, based on an Olea Europaea leaf extract


wound-healing technology, have been acquired by Noventure, specialised in licensing medical devices and food supplements. The medical devices were originally developed by Spanish companies Quesper R&D, and Orpea Ibérica, together with the Andalusian Health Service (Servicio Andaluz de Salud, SAS).


Luciano Conde, CEO of Noventure, said: “This agreement will enable us to keep shaping innovative science assets and bring them to markets around the world, and to take steps towards becoming a key player in medical devices for topical applications. This is only the beginning; we have many innovative products that we will be able to bring to patients, thanks to this patented new technology.”


Ulkox and Oleoabrax, the fi rst Olea Europaea-based products for Noventure, are already available for licensing. Certifi ed as Class IIb medical devices, they are indicated for healing skin wounds of full or partial thickness. As amorphous hydrogels, they protect the affected area from infection and boost healing based on four properties: the protective barrier, skin hydration, pH control and oxygen radical scavenging effect.


More information online: ilmt.co/PL/GEo0 55177pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140  |  Page 141  |  Page 142  |  Page 143  |  Page 144  |  Page 145  |  Page 146  |  Page 147  |  Page 148  |  Page 149  |  Page 150  |  Page 151  |  Page 152  |  Page 153  |  Page 154  |  Page 155  |  Page 156  |  Page 157  |  Page 158  |  Page 159  |  Page 160  |  Page 161  |  Page 162  |  Page 163  |  Page 164  |  Page 165  |  Page 166  |  Page 167  |  Page 168  |  Page 169  |  Page 170  |  Page 171  |  Page 172  |  Page 173  |  Page 174  |  Page 175  |  Page 176  |  Page 177  |  Page 178  |  Page 179  |  Page 180  |  Page 181  |  Page 182  |  Page 183  |  Page 184  |  Page 185  |  Page 186  |  Page 187  |  Page 188  |  Page 189  |  Page 190  |  Page 191  |  Page 192  |  Page 193  |  Page 194  |  Page 195  |  Page 196